Drug intelligence / Profile preview

latanoprost ophthalmic solution 0.005% (TearClear TC-002)

Development stage
Phase 4
Lead developer
TearClear
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

TC-002 is a novel **latanoprost ophthalmic solution 0.005%** developed by TearClear, designed to deliver preservative-free latanoprost from a conventional multi-dose bottle for the treatment of elevated intraocular pressure (IOP), including glaucoma and ocular hypertension. Its platform keeps the commonly used preservative benzalkonium chloride (BAK) in the bottle to maintain sterility and stability, but removes it from the drops when dispensed, delivering *pristine, preservative-free* medication to the eye. This may reduce the prevalence and severity of ocular surface disease (OSD) associated with preserved glaucoma medications. TC-002 met primary and all secondary endpoints in a Phase 3 pivotal trial (CLEAR Study), showing efficacy and tolerability comparable to standard preserved latanoprost but with no exposure of the ocular surface to preservative[1][2][5][6][7][9].

Brand names
TC-002TC002TC 002
Other names
TearClear preservative-free latanoprostTC-002 latanoprost ophthalmic solutionTC002 latanoprost ophthalmic solutionTC 002 latanoprost ophthalmic solution
02

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on latanoprost ophthalmic solution 0.005% (TearClear TC-002).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on latanoprost ophthalmic solution 0.005% (TearClear TC-002).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call